Possible burden of hyperuricaemia on mortality in a community-based population: a large-scale cohort study

Yoichiro Otaki1, Tsuneo Konta2,3*, Kazunobu Ichikawa1, Shouichi Fujimoto1, Kunitoshi Iseki2, Toshiki Moriyama3, Kunihiro Yamagata3, Kazuhiro Tsuruya3, Ichiei Narita3, Masahide Kondo3, Yugo Shibagaki3, Masato Kasahara3, Koichi Asahi3 & Tsuyoshi Watanabe3

Hyperuricaemia is a risk for premature death. This study evaluated the burden of hyperuricaemia (serum urate > 7 mg/dL) for all-cause and cardiovascular mortality in 515,979 health checkup participants using an index of population attributable fraction (PAF). Prevalence of hyperuricaemia at baseline was 10.8% in total subjects (21.8% for men and 2.5% for women). During 9-year follow-up, 5952 deaths were noted, including 1164 cardiovascular deaths. In the Cox proportional hazard analysis adjusted for confounding factors, hyperuricaemia was independently associated with all-cause and cardiovascular mortality (adjusted hazard ratios [95% confidence interval]; 1.36 [1.25–1.49] and 1.69 [1.41–2.01], respectively). Adjusted PAFs of hyperuricaemia for all-cause and cardiovascular deaths were 2.9% and 4.4% (approximately 1 in 34 all-cause deaths and 1 in 23 cardiovascular deaths), respectively. In the subgroup analysis, the association between hyperuricaemia and death was stronger in men, smokers, and subjects with renal insufficiency. Adjusted PAFs for all-cause and cardiovascular deaths were 5.3% and 8.1% in men; 5.8% and 7.5% in smokers; and 5.5% and 7.3% in subjects with renal insufficiency. These results disclosed that a substantial number of all-cause and cardiovascular deaths were statistically relevant to hyperuricaemia in the community-based population, especially men, smokers, and subjects with renal insufficiency.

In conjunction with rising physical inactivity and increasing obesity, the prevalence of hyperuricaemia is increasing in the general population1. Hyperuricaemia is often accompanied by common disorders such as hypertension, obesity, diabetes, dyslipidaemia, and renal insufficiency, making it difficult to evaluate the significance of hyperuricaemia by itself. Previous epidemiological studies from various countries have shown that hyperuricaemia is independently associated with an increased risk of all-cause and cardiovascular mortality2–4, stroke5, and coronary heart disease6, even after adjusting for the aforementioned risk factors. Similar association was observed in the Japanese general population7–13. These observations suggest the significance of hyperuricaemia on life expectancy, independent of other risk factors. However, the burden of hyperuricaemia on life expectancy among the general population with respect to the prevalence of hyperuricaemia is unknown.

In epidemiological studies, to assess the strength of association between exposure to a specific risk factor and the occurrence of a particular event, a measure of relative risk is often used. However, this measure does not consider the prevalence of risk factors; therefore, it is not appropriate to use relative risk to evaluate disease burden. In contrast, the population attributable fraction (PAF) is an integrated measure that includes both the strength of the association of the risk factor with the event and the prevalence of the risk factor among the population. The PAF represents the proportion of a specific outcome in a population, which is relevant to the exposure to the risk factor(s)14. In the Japanese population, the PAFs of hypertension15–20 and smoking21,22 for all-cause and cardiovascular mortality have been reported. However, the possible burden of hyperuricaemia on all-cause and cardiovascular mortality has not been evaluated using the measure of PAF.

1Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan. 2Department of Public Health and Hygiene, Yamagata University School of Medicine, 2-2-2, Iida-Nishi, Yamagata 990-9585, Japan. 3Steering Committee of Research on “Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) Based On the Individual Risk Assessment By Specific Health Checkup”, Fukushima Medical University, Fukushima, Japan. *email: kkonta@med.id.yamagata-u.ac.jp
To explore this further, we used a national prospective database of 515,979 Japanese annual health check-ups participants from the Japan Specific Health Checkups study (J-SHC study) and assessed the possible burden of hyperuricaemia for all-cause and cardiovascular mortality.

**Results**

The subjects’ clinical characteristics at baseline are presented in Table 1. The prevalence of hyperuricaemia was 55,940 (10.8%) (men, 21.8%; women, 2.5%) among a total of 515,979 participants. Hyperuricaemia participants were more likely to be younger, male, smokers, and drinkers and have high blood pressure, diabetes, dyslipidaemia, high BMI, and low estimated glomerular filtration rate (eGFR) compared with those without hyperuricaemia.

During the 9-year follow-up, 5952 (1.2%) deaths were noted (men, 1.8%; women, 0.7%), including 1164 deaths (0.2%) (men, 0.4%; women, 0.1%) owing to cardiovascular causes.

The association between serum urate levels and mortality is shown in Table 2. In the multivariate model adjusted for possible confounders, a significant increase in the hazard ratio (HR) of hyperuricaemia for all-cause and cardiovascular mortality was observed compared with no hyperuricaemia (HR, 1.36 [95% confidence interval (CI) 1.25–1.49] for all-cause mortality and HR, 1.69 [95% CI 1.41–2.01] for cardiovascular mortality). The PAF of hyperuricaemia was 2.9% for all-cause mortality and 4.4% for cardiovascular mortality (approximately 1 in 34 of all-cause deaths, and 1 in 23 of cardiovascular deaths). The PAFs of other common risk factors for all-cause and cardiovascular mortality were 6.7% and 7.6%, respectively, for smoking; 4.9% and 4.7%, respectively, for diabetes; and 3.4% and 11.1%, respectively, for hypertension. In contrast, the HRs for all-cause and cardiovascular mortality owing to dyslipidaemia and alcohol consumption were not increased; therefore, the PAFs of these factors were not calculated.

In the Cox proportional hazard analysis, possible interactions with hyperuricaemia were detected with respect to sex (P < 0.01) and eGFR (P < 0.01) for all-cause mortality and eGFR (P < 0.01) for cardiovascular mortality. Therefore, we performed subgroup analyses of baseline characteristics (Table 3) and found that the PAFs of hyperuricaemia varied depending on the subgroups: as follows 1.3–5.8% for all-cause mortality and 1.6–8.1% for cardiovascular mortality. In particular, the association between hyperuricaemia and death was stronger in men, smokers, and subjects with renal insufficiency (eGFR < 60 mL/min/1.73 m²) than in their counterparts.

### Table 1. Baseline characteristics of the study population. Mean ± standard deviation. BMI body mass index; eGFR estimated glomerular filtration rate.

|                      | Total participants | Studied subjects | Hyperuricaemia (> 7 mg/dL) | Non-hyperuricaemia (≤ 7 mg/dL) |
|----------------------|--------------------|------------------|-----------------------------|--------------------------------|
| Number (%)           | 685,889            | 515,979          | 55,940 (10.8)               | 460,039 (89.2)                 |
| Men (%)              | 42.7               | 43.0             | 86.6                        | 13.4                           |
| Age (years)          | 62.3 ± 8.8         | 62.3 ± 8.9       | 61.2 ± 9.5                  | 62.4 ± 8.8                     |
| Smoking (%)          | 15.5               | 15.4             | 25.6                        | 14.2                           |
| Alcohol consumption (%) | 46.5               | 46.5             | 70.0                        | 43.7                           |
| BMI (kg/m²)          | 23.5 ± 3.5         | 23.5 ± 3.5       | 25.1 ± 3.5                  | 23.2 ± 3.4                     |
| eGFR (mL/min/1.73 m²) | 76.0 ± 17.3        | 75.9 ± 17.0      | 68.4 ± 17.1                 | 76.9 ± 16.7                    |
| Hypertension (%)     | 29.2               | 29.2             | 39.1                        | 28.0                           |
| Diabetes (%)         | 13.1               | 12.2             | 13.4                        | 12.0                           |
| Dyslipidaemia (%)    | 47.5               | 47.7             | 62.5                        | 45.9                           |

### Table 2. Population attributable risk of hyperuricaemia for all-cause and cardiovascular mortality. HR hazard ratio, CI confidence interval, PAF population attributable risk fraction, BMI body mass index, eGFR estimated glomerular filtration rate.

|                      | Prevalence (%) | All-cause mortality | Cardiovascular mortality |
|----------------------|----------------|---------------------|-------------------------|
|                      |                | Adjusted HR (95% CI) | PAF (%)                 | Adjusted HR (95% CI) | PAF (%) |
| Hyperuricaemia       | 10.8           | 1.36 (1.25–1.49)    | 2.9                     | 1.69 (1.41–2.01)    | 4.4 |
| Smoking              | 15.4           | 1.76 (1.63–1.90)    | 6.7                     | 1.97 (1.68–2.33)    | 7.6 |
| Diabetes             | 12.2           | 1.68 (1.56–1.81)    | 4.9                     | 1.63 (1.38–1.92)    | 4.7 |
| Hypertension         | 29.2           | 1.13 (1.07–1.21)    | 3.4                     | 1.61 (1.40–1.85)    | 11.1 |
| Dyslipidaemia        | 8.99 (0.84–0.95)| 1.05 (0.92–1.21)    |                         |                      |      |
| Alcohol consumption  | 0.72 (0.68–0.78)| 0.69 (0.59–0.80)    |                         |                      |      |
| Men (vs. Women)      | 2.61 (2.42–2.82)| 2.55 (2.14–3.03)    |                         |                      |      |
| Age (per 1-year increase) | 1.06 (1.06–1.07) | 1.07 (1.05–1.08)   |                         |                      |      |
| BMI (per 1 kg/m² increase) | 0.97 (0.96–0.98) | 1.00 (0.98–1.03)   |                         |                      |      |
| eGFR (per 1 mL/min/1.73 m² increase) | 1.001 (0.998–1.003) | 0.992 (0.987–0.996) |                    |                      |      |
determined from causality and cost-effectiveness data obtained from intervention trials. However, whether all high-risk subjects require urate-lowering medication remains unclear. This should be

men (21.8%), smokers (18.0%), and subjects with renal insufficiency (23.9%) were at a higher risk for mortality. Based on the current findings, a substantial number of additional mortality in almost all subgroups even after adjusting for confounding factors. However, the frequency of hyperuricaemia, which differed in each group, greatly affected the PAF. In particular, the PAF of hypertension for all-cause mortality was 12% in elderly men and 3% in elderly women, whereas the PAF of hypertension for cardiovascular death was 28% in elderly men and 7% in elderly women. A US report showed that the PAF of diabetes was 3.6% for all-cause mortality and 5.2% for cardiovascular mortality. Because of the differences in age, ethnicity, region of the studied population, and definition of diseases and events, the absolute values of PAF cannot be compared among studies. However, the PAFs of hypertension and diabetes in the current study were similar to those in these previous studies, indicating that our results do not seem to be significantly biased. Considering the current increasing prevalence of hyperuricaemia, the possible burden of hyperuricaemia is also expected to increase.

In the subgroup analyses, hyperuricaemia was independently associated with all-cause and cardiovascular mortality in almost all subgroups even after adjusting for confounding factors. However, the frequency of hyperuricaemia, which differed in each group, greatly affected the PAF. In particular, the PAF in the subgroup of men who had a high frequency of hyperuricaemia was the highest among all subgroups. As the prevalence of hyperuricaemia is increasing in males, the implications of hyperuricaemia is expected to increase in the future. In contrast, the HR of hyperuricaemia for mortality is higher in women than in men, although the prevalence of hyperuricaemia is very low in women. Accordingly, the PAF of hyperuricaemia is low, and its association with mortality in women seems to be limited. Although many studies, including our study, defined hyperuricaemia as serum urate > 7 mg/dL in both men and women, the distribution of serum urate differs between men and women. Therefore, different cut-off values might be more appropriate for both groups.

The PAFs of hyperuricaemia for mortality are also increased in smokers and subjects with renal insufficiency, namely by a factor of 2–3 times higher than that of their counterparts. The precise mechanism is unknown. In addition to high prevalence of hyperuricaemia in these subjects, smoking, renal insufficiency, and hyperuricaemia may have synergistic association with mortality. Based on the current findings, a substantial number of men (21.8%), smokers (18.0%), and subjects with renal insufficiency (23.9%) were at a higher risk for mortality. However, whether all high-risk subjects require urate-lowering medication remains unclear. This should be determined from causality and cost-effectiveness data obtained from intervention trials.

### Table 3. Subgroup analyses for population attributable fraction of hyperuricaemia. eGFR estimated glomerular filtration rate; HR hazard ratio; CI confidence interval; PAF population attributable fraction; (+), present; (−), absent. *Adjusted for age, gender, body mass index, smoking, alcohol consumption, eGFR, hypertension, diabetes, and dyslipidaemia.

| Subgroups             | Prevalence of hyperuricaemia (%) | All-cause mortality | Cardiovascular mortality |
|-----------------------|----------------------------------|---------------------|--------------------------|
|                       |                                  | Adjusted HR* (95% CI) | PAF (%)             | Adjusted HR* (95% CI) | PAF (%) |
| Men                   | 21.8                             | 1.32 (1.28–1.45)     | 5.3                     | 1.59 (1.32–1.92)     | 8.1    |
| Women                 | 2.5                              | 2.09 (1.62–2.69)     | 1.3                     | 2.65 (1.62–4.33)     | 1.6    |
| < 65 years            | 11.6                             | 1.34 (1.15–1.55)     | 2.9                     | 1.71 (1.26–2.31)     | 4.8    |
| ≥ 65 years            | 10.1                             | 1.37 (1.22–1.52)     | 2.7                     | 1.66 (1.34–2.07)     | 4.0    |
| Hypertension (−)      | 9.3                              | 1.38 (1.23–1.55)     | 2.6                     | 2.06 (1.62–2.62)     | 4.8    |
| Hypertension (+)      | 14.5                             | 1.34 (1.16–1.53)     | 3.7                     | 1.37 (1.06–1.77)     | 3.9    |
| Diabetes (−)          | 11.0                             | 1.39 (1.26–1.53)     | 3.1                     | 1.77 (1.44–2.16)     | 4.8    |
| Diabetes (+)          | 12.2                             | 1.25 (1.03–1.51)     | 2.4                     | 1.44 (0.99–2.09)     | 3.7    |
| Dyslipidaemia (−)     | 7.8                              | 1.38 (1.22–1.57)     | 2.1                     | 1.95 (1.50–2.54)     | 3.8    |
| Dyslipidaemia (+)     | 14.2                             | 1.33 (1.18–1.50)     | 3.5                     | 1.52 (1.20–1.92)     | 4.9    |
| Smoking (−)           | 9.6                              | 1.30 (1.17–1.45)     | 2.2                     | 1.67 (1.35–2.06)     | 3.9    |
| Smoking (+)           | 18.0                             | 1.47 (1.26–1.72)     | 5.8                     | 1.71 (1.25–2.34)     | 7.5    |
| Alcohol consumption (−)| 6.0                              | 1.31 (1.12–1.51)     | 1.4                     | 1.72 (1.29–2.30)     | 2.5    |
| Alcohol consumption (+)| 16.0                            | 1.39 (1.24–1.55)     | 4.5                     | 1.65 (1.32–2.07)     | 6.3    |
| eGFR ≥ 60 mL/min/1.73 m² | 8.7                              | 1.30 (1.16–1.45)     | 1.5                     | 1.65 (1.31–2.08)     | 3.4    |
| eGFR < 60 mL/min/1.73 m² | 23.9                             | 1.21 (1.04–1.41)     | 5.5                     | 1.44 (1.09–1.90)     | 7.3    |
The strength of this study is that we used a large number of samples collected from different regions of Japan, with sufficient events and ability to correct for multiple confounders. Furthermore, various subgroup analyses increased the robustness of the obtained results. However, this study had some limitations. First, serum urate levels were measured only at baseline. Second, although the authors strongly related with serum urate levels were adjusted in this study, the unmeasured confounding factors could exist. For instance, there was no information on medication use for hyperuricaemia and others (e.g., diuretics) in the study subjects. Furthermore, the self-reported lifestyle factors do not perfectly reflect the actual status. Therefore, the residual confounding factors may be involved in the observed association. Third, the participants were Japanese; therefore, the findings might not be applicable to other populations. Fourth, owing to the observational nature of the study, our findings did not show a direct causal relationship between uric acid levels and mortality. Although this study used the measure of PAF to assess the possible burden of hyperuricaemia, whether hyperuricaemia itself is a direct cause of mortality is undetermined. There is a possibility that the elevation in serum urate is not a cause but a rather reflection of other unmeasured risk factors. Clinical trials utilising interventions to lower urate are necessary to clarify this point.

Conclusions
This study shows that a substantial number of all-cause and cardiovascular deaths are statistically relevant to hyperuricaemia in this community-based population, especially in men, smokers, and subjects with renal insufficiency. These results indicate that if uric acid levels are causally related to mortality, then lowering uric acid levels may reduce the risk of premature death among a large number of at-risk subjects. However, the causality cannot be determined from this observational study. To verify our findings of the association between urate and mortality, a prospective interventional study using urate-lowering therapies is warranted.

Methods
Study population. This study was part of an ongoing “Research on Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) based on the Individual Risk Assessment by Specific Health Checkup” study. The study population included participants from the Specific Health Check and Specific Health Guidance, an annual health check-up for all inhabitants of Japan who were aged between 40 and 74 years, covered by the Japanese national health insurance. Between 2008 and 2014, a total of 685,889 subjects, (male, 42.7%; female, 57.3%; age range, 40–74 years) participated in the baseline health check-ups from eight areas: Yamagata, Fukushima, Niigata, Ibaraki, Tойonaka, Fukuoka, Miyazaki, and Okinawa. The details of this study have been described elsewhere. The study was conducted in accordance with the guidelines of the Declaration of Helsinki. The ethics committees of Yamagata University (Approval No. 2008-103) approved this study and waived the need for informed consent from each participant because all data were anonymised before analysis. Among the 685,889 baseline participants, 169,910 (24.8%) subjects (male, 41.7%; female, 58.3%) were excluded from this study because essential data, mainly serum urate levels, were incomplete. Therefore, data of 515,979 subjects (male, 43.0%; female, 57.0%) were included in this analysis. The association between serum urate levels at baseline and all-cause and cardiovascular mortality during the 9-year follow-up (median 3.7 years) was examined, and the PAF was calculated.

Measurements. The subjects completed a self-reported questionnaire to document their medical history, current medications, current smoking habits (smoker or non-smoker), and current alcohol consumption (drinker or non-drinker). Body weight, height, and systolic and diastolic blood pressure were measured at health check-ups. The presence of diabetes and dyslipidaemia was ascertained by laboratory parameters, including plasma glucose, haemoglobin A1C (HbA1C), triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and information on medical treatment. Hypertension was defined as systolic blood pressure $\geq 140$ mmHg or diastolic blood pressure $\geq 90$ mmHg at the health check-up site or the use of antihypertensive medication. Diabetes was defined as a plasma glucose level $\geq 126$ mg/dL, HbA1C (NGSP value) $\geq 6.5$%, or the use of anti-diabetic medication. Dyslipidaemia was defined as triglyceride levels $\geq 150$ mg/dL, HDL-C levels $< 40$ mg/dL, LDL-C levels $\geq 140$ mg/dL, or the use of lipid-lowering medication. Serum urate levels were mainly measured using an enzymatic method. In the Guideline of Japanese Society of Gout and Nucleic Acid Metabolism, hyperuricaemia is defined as serum urate levels of more than 7.0 mg/dL. In addition, our previous study using data of the same community-based population, showed that a significant increase in the risk for all-cause and cardiovascular mortality was observed at serum urate levels $\geq 7.0$ in men. Therefore, in this analysis hyperuricaemia was defined as serum urate levels $> 7$ mg/dL. Serum creatinine levels were measured using an enzymatic method, and eGFR was obtained using the Japanese equation. All blood and urine analyses were performed in local laboratories. The methods for these analyses were not calibrated among laboratories; however, the analyses were performed according to the Japan Society of Clinical Chemistry recommended methods for laboratory tests, which have been widely adopted by laboratories across Japan.

Classification of cause of death. Confirmation of death and classification of the cause of death were performed using the methods previously reported. The incidence of death was monitored annually at the end of 2016, and the causes of death were determined by reviewing death certificates. Death certificates were collected with permission from the Management and Coordination Agency of the Japanese Government. The death code (International Classification of Diseases, 10th Revision) and date of death were reviewed. The cause of death was classified using the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) code. Cardiovascular mortality was defined as death due to the circulatory system (ICD-10 codes 100–199), such as acute myocardial infarction (I21), chronic ischaemic heart disease (I25), cardiomyopa-
thy (142), heart failure (150), subarachnoid haemorrhage (160), intracerebral haemorrhage (161), and cerebral infarction (163).

**Statistical analysis.** To examine the HRs of hyperuricemia for mortality, multivariate Cox proportional hazard analyses adjusted for possible confounding factors such as age, sex, smoking habits, alcohol consumption, eGFR, body mass index, hypertension, diabetes, and dyslipidaemia were performed. The assumption of proportional hazards was tested by the Schoenfeld residuals and the graphs of the log–log plot of the relative hazards by time, and it showed no violation of proportionality. PAF was calculated using the formula: PAF = pd × (relative risk – 1)/relative risk, where pd is the proportion of cases exposed to the risk factor[25]. To confirm the association, subgroup analysis was performed on baseline characteristics. The significance of the interaction with confounding comorbidities was tested using multivariate Cox models. Continuous data are expressed as mean ± standard deviation. All statistical analyses were performed using Stata version 14 software (Stata Corp LP, College Station, TX, USA). P values < 0.05 were considered statistically significant. In multiple testing in subgroup analysis, P value threshold was adjusted using the Bonferroni correction (P < 0.05/ the number of testing).

**Data availability**
Data cannot be shared publicly due to ethical restrictions on sharing data publicly.

Received: 12 December 2020; Accepted: 8 April 2021
Published online: 26 April 2021

**References**

1. Zha, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. *Arthritis Rheum.* 63, 3136–3141 (2011).
2. Cho, S. K., Chang, Y., Kim, I. & Byu, S. U-shaped association between serum uric acid level and risk of mortality: A cohort study. *Arthritis Rheumatol.* 70, 1122–1132 (2018).
3. Zuo, T. et al. Hyperuricemia and coronary heart disease mortality: A meta-analysis of prospective cohort studies. *BMC Cardiovasc. Disord.* 16, 207 (2016).
4. Zhao, G., Huang, L., Song, M. & Song, Y. Baseline serum uric acid level as a predictor of cardiovascular disease-related mortality and all-cause mortality: a meta-analysis of prospective studies. *Arthritis Rheum.* 63, 61–68 (2013).
5. Niskanen, L. K. et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. *Arch. Intern. Med.* 164, 1546–1551 (2004).
6. Li, M. et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality: A systematic review and dose-response meta-analysis. *Sci. Rep.* 6, 19520 (2016).
7. Freedman, D. S., Williamson, D. F., Gunter, E. W. & Byers, T. Relation of serum uric acid to mortality and ischemic heart disease. *Am. J. Epidemiol.* 141, 637–644 (1995).
8. Fang I, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. *JAMA* 283, 2404–2410 (2000).
9. Kim, S. Y. et al. Hyperuricemia and risk of stroke: A systematic review and meta-analysis. *Arthritis Rheum. Res.* 61, 885–892 (2009).
10. Kim, S. Y. et al. Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. *Arthritis Care Res. (Hoboken).* 62, 170–180 (2010).
11. Zhang, W. et al. Serum uric acid and mortality form cardiovascular disease: EPOCH-JAPAN study. *J. Atheroscler. Thromb.* 23, 692–703 (2016).
12. Kamei, K. et al. Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study. *Clin. Exp. Nephrol.* 20, 904–909 (2016).
13. Konta, T. et al. Association between serum uric acid levels and mortality: a nationwide community-based cohort study. *Sci. Rep.* 10, 6066 (2020).
14. Laaksonen, M. A., Knekt, P., Härkanen, T., Virtala, E. & Oja, H. Estimation of the population attributable fraction for mortality in a cohort study using a piecewise constant hazards model. *Am. J. Epidemiol.* 171, 837–847 (2010).
15. Fujiyoshi, A. et al. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. *Hypertens. Res.* 35, 947–953 (2012).
16. Hozawa, A. Attributable fractions of risk factors for cardiovascular diseases. *J. Epidemiol.* 21, 81–86 (2011).
17. Martinuik, A. L. et al. Hypertension: Its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. *J. Hypertens.* 25, 73–79 (2007).
18. Sairenchi, T. et al. Impact and attribute of each obesity-related cardiovascular risk factor in combination with abdominal obesity on total health expenditures in adult Japanese National Health insurance beneficiaries: The Ibaraki Prefectural health study. *J. Epidemiol.* 27, 354–359 (2017).
19. Ikeda, A., Iso, H., Yamagishi, K., Inoue, M. & Tsugane, S. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: The JPHC Study. *Am. J. Hypertens.* 22, 273–280 (2009).
20. Hatano, Y. et al. The population-attributable fraction for premature mortality due to cardiovascular disease associated with stage 1 and 2 hypertension among Japanese. *Am. J. Hypertens.* 34, 53–63 (2020).
21. Uno, F. et al. Smoking and risk of all-cause mortality: The Ichi Medical School (JMS) Cohort Study. *J. Epidemiol.* 15, 173–179 (2005).
22. Saydah, S. H., Eberhardt, M. S., Loria, C. M. & Brancati, F. L. Age and the burden of death attributable to diabetes in the United States. *Am. J. Epidemiol.* 156, 714–719 (2002).
23. Yamanaka H. The Guideline Revising Committee of Japanese Society of Gout and Nucleic Acid Metabolism. Essence of the revised guideline for the management of hyperuricemia and gout. *Ipn. Med. Assoc. J.* 55, 324–329 (2012).
24. Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am. J. Kidney Dis.* 53, 982–992 (2009).
25. Rockhill, B., Newman, B. & Weinberg, C. Use and misuse of population attributable fractions. *Am. J. Public Health.* 88, 15–19 (1998).

**Author contributions**
Y.O., T.K., and K.I. conceived and designed the study concept and wrote the draft of the paper. Y.O., T.K., and K.I. analysed the data. All authors contributed substantively to writing and reviewing the paper.
Funding
This study was supported by a Health and Labour Sciences Research Grant for “Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) based on the Individual Risk Assessment by Specific Health Checkup” from the Ministry of Health, Labour and Welfare of Japan and a Grant-in-Aid for “Research on Advanced Chronic Kidney Disease (REACH-J), Practical Research Project for Renal Disease” from the Japan Agency for Medical Research and Development (AMED).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021